narcolepsy type 1

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Eli Lilly’s retatrutide moves closer to a planned 2027 U.S. filing after completing its core Phase 3 programme for obesity, knee pain and sleep apnea. Representative image.

Retatrutide development: Phase 3 results, 2027 FDA filing, TRIUMPH trials and what comes next

India and Canada are accelerating CEPA negotiations as LNG, nuclear energy and critical minerals become central to their expanding economic relationship. Representative image.

Canada targets India trade deal by year-end as LNG, nuclear and critical minerals talks deepen

The White House press-access dispute intensified after MS NOW journalists said their credentials were disabled following Donald Trump’s media ban. Representative image.

Trump White House media ban takes effect as MS NOW journalists are turned away

Smoke near Riyadh’s King Khalid International Airport followed Saudi aerial danger alerts as the conflict with Yemen’s Houthis intensifies. Representative image.

Smoke rises near Riyadh airport after Saudi aerial alerts as Houthi conflict escalates

Takeda’s oveporexton Phase 3 trials show broad success in narcolepsy type 1, paving way for 2025 FDA submission

Takeda announces pivotal Phase 3 trial results for oveporexton (TAK-861), showing statistically significant improvements in narcolepsy type 1 symptoms. Regulatory filings planned.

μFR system
αvβ6-integrin
α4β7 integrin
Þorgerður Katrín Gunnarsdóttir
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
ZYNRELEF

July 14, 2025